BKM120

Item number	Size	Datasheet	Manual	SDS	Delivery time	Quantity	Price
LKT-B4248.1	1 mg		-		3 - 8 business days*		108.00€
LKT-B4248.5	5 mg		-		3 - 8 business days*		301.00€

If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk

BKM120 is an inhibitor of PI3K that is currently in clinical trials as a potential treatment for... more

Close menu

Product information "BKM120"

BKM120 is an inhibitor of PI3K that is currently in clinical trials as a potential treatment for brain metastases of HER2+ breast cancer and other solid tumors. BKM120 exhibits anticancer chemotherapeutic activity, inducing G2/M phase cell cycle arrest, polyploidy, and apoptosis in glioblastoma cells. Additionally, BKM120 decreases levels of Mcl-1 and enhances TRAIL-dependent apoptosis in lung cancer cells. BKM also binds tubulin, inhibiting microtubule polymerization.

Keywords:	Buparlisib, NVP-BKM120
Supplier:	LKT Laboratories
Supplier-Nr:	B4248

Properties

Application:	PI3K p110 inhibitor
MW:	410.39 D
Purity:	>98%
Format:	Solid

Database Information

CAS :	944396-07-0\| Matching products
KEGG ID :	K00922 \| Matching products

Handling & Safety

Storage:	+4°C
Shipping:	+4°C (International: +4°C)
Signal Word:	Danger
GHS Hazard Pictograms:
H Phrases:	H301, H341, H372
P Phrases:	P201, P202, P260, P264, P270, P281, P301+P310, P308+P313, P314, P321, P330, P405, P501